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Progressions

On the Road from Phenotypic Plasticity to Stem Cell
Therapy
Lorraine Iacovitti
Department of Neuroscience, Director, Jefferson Stem Cell and Regenerative Neuroscience Center, Vickie and Jack Farber Institute for
Neuroscience, Thomas Jefferson University, Philadelphia, Pennsylvania 19107

In 1981, I published a paper in the first issue of The Journal of Neuroscience with my postdoctoral mentor, Richard Bunge.
At that time, the long-standing belief that each neuron expressed only one neurotransmitter, known as Dale’s Principle
(Dale, 1935), was being hotly debated following a report by French embryologist Nicole Le Douarin showing that neural crest
cells destined for one transmitter phenotype could express characteristics of another if transplanted to alternate sites in the
developing embryo (Le Douarin, 1980). In the Bunge laboratory, we were able to more directly test the question of phenotypic plasticity in the controlled environment of the tissue culture dish. Thus, in our paper, we grew autonomic catecholaminergic neurons in culture under conditions which promoted the acquisition of cholinergic traits and showed that cells did
not abandon their inherited phenotype to adopt a new one but instead were capable of dual transmitter expression. In this
Progressions article, I detail the path that led to these findings and how this study impacted the direction I followed for the
next 40 years. This is my journey from phenotypic plasticity to the promise of a stem cell therapy.

Introduction
I came of age in science at an exciting time: it was a decade after
the pivotal discovery by Falck and Hillarp that neurons containing catecholamine neurotransmitters could be made to temporarily fluoresce when exposed to formaldehyde vapor (Falck,
1962). This technique, while ground-breaking, proved to be relatively impractical for experimentation. So, in 1974, it was my
good fortune to join the prestigious laboratory of Donald Reis as
a new PhD student at Cornell University Medical College...and
to do so at a time when Tong Joh was there generating the
“world’s best” tyrosine hydroxylase (TH) antibodies and Virginia
Pickel was perfecting the science of localizing those antibodies in
catecholamine neurons. It was during those heady days when
immunohistochemistry replaced histofluorescence that I learned
to love all things catecholamine, a passion I never lost throughout my career.
But it was not until joining the laboratory of Drs. Richard
and Mary Bunge at Washington University Medical School
as a postdoctoral fellow that I began to actually manipulate
catecholamine neurons. Landing in the Bunge laboratory, a
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warm and welcoming home to so many of us, was yet another
stroke of luck. Dick, a pioneer and world’s leading authority
in nerve tissue culture, instilled in all of us, the F1 generation
of nerve tissue culturists, a life-long zeal for the in vitro
approach. This was no easy feat when you consider that, in
1980, we were still hand-molding and acid washing all of our
own tissue culture dishes. Beyond the laboratory, I found
myself surrounded at Washington University by an incredibly talented and collaborative group of neuroscientists
assembled by Max Cowan, then the Chair of the Department
of Anatomy and Neurobiology. Among this astute group of
neighbors was the brilliant embryologist, Viktor Hamburger,
who with Rita Levi-Montalcini, had discovered NGF and
founded the field of nerve growth factors.
With that as my backdrop, I fittingly began my postdoctoral
studies in the Bunge laboratory by interrogating the age-old
question of nature versus nurture and the role of each in the development of the catecholamine neuron. More specifically, we
sought to determine how a neuron came to express a catecholamine phenotype during development and whether that fate
could be altered by its environment, a question the answer for
which ultimately led to the discovery of another important
growth factor. The first installment in that work, entitled “Dual
expression of neurotransmitter synthesis in cultured autonomic
neurons,” was published in the inaugural issue of The Journal of
Neuroscience (Iacovitti et al., 1981).
Catecholamine phenotypic plasticity
At its core, this study aimed to resolve a brewing controversy in
the literature: whether neurons could be induced to express
more than one neurotransmitter and whether the acquisition of
the new transmitter type occurred at the expense of the inherited
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phenotype. Focusing solely on neurons was new territory for the
Bunge laboratory, renowned for its pioneering work on Schwann
cells and myelination. Therefore, Dick turned to our downstairs
neighbor in the Pharmacology Department, Gene Johnson, to
help guide my day-to-day biochemical analyses of these neurons.
Gene, celebrated for his work on neurotrophic factors, generously allowed me to move in and take over a whole section of his
laboratory with my TH enzyme assays and Northern blots. He
welcomed me, as did everyone in his laboratory, with forbearance, daily good humor, and a great deal of scientific wisdom.
We used as our experimental model sympathetic adrenergic
neurons of the superior cervical ganglion (SCG) which were
grown in culture under conditions conducive to the induction of
a cholinergic phenotype. As the title of our article suggests, we
found that virtually all SCG neurons were capable of dual neurotransmitter production and thus the potential for dual function
(Fig. 1) (Iacovitti et al., 1981, 1982). Simultaneously, our colleagues at Harvard (Drs. Furshpan, Potter, Patterson, and
Landis) explored similar questions in adrenergic and cholinergic
sympathetic neurons in vitro and in vivo (Landis, 1980; Potter et
al., 1981). Although there was some back and forth between the
Harvard and Washington University groups (much of which
played itself out in the pages of The Journal of Neuroscience and
at Society of Neuroscience meetings), ultimately, both groups
came to agree that the adrenergic phenotype was sustained longterm as evidenced by the continued expression of enzymatically
active TH and catecholamine uptake in sympathetic neurons despite the acquisition of new cholinergic properties (Higgins et al.,
1981; Iacovitti et al., 1981, 1982; Johnson et al., 1981; Potter et
al., 1981; Landis and Keefe, 1983; Wolinsky and Patterson,
1983). The phenotypic plasticity displayed by these postmitotic
autonomic neurons was paradigm shifting at the time, given the
prevailing belief in Dale’s Principle of “one neuron, one transmitter” (Dale, 1935).
Having completed my postdoctoral fellowship, I moved back
to Cornell University Medical College in New York as an
Assistant Professor in the Neurology Department. There I had the
enormous good fortune to collaborate with Gladys Teitelman,
who became a lifelong friend and a pivotal mentor during my
early career years. Capitalizing on her rich background as a developmental biologist, together Gladys and I expanded the study of
phenotypic plasticity to her favorite developmental model, the
chick embryo. We found that, like adrenergic sympathetic neurons, cholinergic parasympathetic neurons in the chicken ciliary
ganglion could similarly be induced by environmental cues to
express a dual transmitter phenotype (Iacovitti et al., 1985, 1987;
Teitelman et al., 1985).
Catecholamine differentiation and the muscle-derived
differentiation factor (MDF) story
In 1989, with a husband and two small daughters in tow, I
returned to my hometown of Philadelphia to open a laboratory
in the newly formed Neuroscience Institute at Hahnemann
University. There, I set my horizons northward on neurons of
the brain. Up to that point, the field had convincingly shown
that PNS neurons were phenotypically plastic, but no one had
yet to ask whether neurons of the more static brain shared this
remarkable ability. Using cultures of primary mouse cortical and
striatal neurons, we found that “something” present in muscle
extract, we later coined MDF, was capable of promoting the
expression of catecholamine traits (TH mRNA and TH protein)
in noncatecholamine neurons of the brain (Iacovitti et al., 1989;
Iacovitti, 1991). We concluded that phenotypic plasticity
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Figure 1. Time course of changes in TH, dopamine- b -hydroxylase (DBH), and ChAT activities in cultures of dissociated perinatal rat SCG. Each experiment represents cultures derived
from one group of fetuses and maintained in an identical manner. Each point represents the
mean 1 SEM of five preparations. In Experiments 1 and 2, ChAT activity (0) increased in an
identical manner, reaching levels of ;9 pmol of acetylcholine (Ach)/neuron/hr by 7 weeks in
culture. While the magnitude of the increases in the activities of TH (0) and DBH (0)
remained the same for both experiments, the maximal levels of activity reached at 7 weeks
in vitro differed in Experiments 1 and 2. The activity of all three enzymes in both experiments
differed significantly between 3 and 7 weeks in vitro. In Experiment 1: for TH, p , 0.05; for
DBH, p , 0.001; for ChAT, p , 0.05. In Experiment 2: for TH, p , 0.05; for DBH, p , 0.01;
and for CAT, p , 0.001. Reprinted with permission from Iacovitti et al. (1981).

represented a more encompassing principle, such that neurons
of the CNS, just as those in periphery, could undergo phenotypic
interconversion in response to biologically active molecules in
their environment.
After several years of protein purification by a gifted biochemist in my laboratory, Xinyu Du, and wonderful collaborators at Amgen, we showed in a series of five Journal of
Neuroscience papers, that MDF activity resulted not from one
substance but from the synergy of fibroblast growth factor 1 and
small activating molecules of the PKA/PKC pathways (Iacovitti
et al., 1989; Iacovitti, 1991; Du et al., 1994; Du and Iacovitti,
1995; Guo et al., 1998). I can remember to this day the disappointment I felt when MDF turned out not to be a novel protein
that the laboratory could run with for years. It was an important
reminder that science is the search for truth, no matter how
inconvenient that truth is for one’s personal career goals. We
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went on to show that, during this transdifferentiation, signals
were transmitted via MAP kinase to the TH-AP1 site to increase
activators and reduce repressors, helping to shift the balance in
favor of TH gene expression at this and possibly other important
regulatory sites on the gene (Guo et al., 1998). Somewhat surprisingly, we subsequently found that infusion of these factors into
the striatum of unilaterally 6-OHDA-lesioned rats caused a significant and long-lasting reduction in motor deficits, suggesting
that they might be important in regulating the production of dopamine in the injured brain and, thus, be of use in the treatment
of Parkinson’s disease (PD) (B. K. Jin and Iacovitti, 1995).
The revolution of stem cells
Nearly a decade later, I moved across town to a new academic
home at Thomas Jefferson University Medical School where I
remain today as a Professor of Neuroscience. Little did I understand then that a scientific revolution was on the horizon that
would reshape the rest of my days in science. In 1998, Jamie
Thomson at the University of Wisconsin published his trailblazing study in Science demonstrating that it was possible to create a
line of human embryonic stem cells (hESCs) from the human
blastocyst (Thomson, 1998). By that point, I was quite comfortable in the world of developmental neuroscience, but I knew
almost nothing about stem cells. So intrigued was I at the prospect of using hESCs to study and potentially treat neurodegenerative disease, however, that I willingly jumped in head first to the
brave new world of stem cells. Together with my young technician Angela Donaldson, we began to fathom our way around
these fascinating but highly challenging cells, learning much to
our chagrin how easily they spontaneously differentiated in the
dish, regardless of the experiments we had planned for them.
Like so many others, we were anxious to direct the differentiation of hES cells into dopamine neurons (Perrier et al., 2004;
Zeng et al., 2004; Park et al., 2005; Iacovitti et al., 2007; Friling et
al., 2009; Cai et al., 2010; Cooper et al., 2010; Lee et al., 2010;
Morizane et al., 2010); the cell lost from the midbrain substantia
nigra (SN) in PD (Hirsch et al., 1988). Theoretically, dopaminedifferentiated stem cells could be used to replace those in the diseased SN, the majority of which have degenerated by the time
PD patients present with their first motor symptoms. Fueling the
PD field’s enthusiasm over the promise of stem cells were earlier
transplant studies showing that grafts of human fetal midbrain
tissue had an ameliorative effect on PD patients (Freed et al.,
2001; Olanow et al., 2003). However, the harvest of fetal tissue
proved incredibly variable, finite in amount and totally impractical in the clinic, sometimes producing unwelcome outcomes
(Folkerth and Durso, 1996; Freed et al., 2001; Hagell et al., 2002;
Ma et al., 2002; Olanow et al., 2003). Therefore, stem cells, representing an unlimited and more uniform source of transplantable
tissue, seemed the ideal answer to our troubles.
Society, however, viewed this brave new world with more
trepidation; and on August 9, 2001, President George W. Bush
imposed a ban on the use of National Institutes of Health funds
for the study of all new hES cell lines. Fortunately, work was
allowed to proceed with Thomson’s original H9 hES line, which
remains to this day, the gold standard in the field. Nonetheless,
the ban slowed progress, and, importantly, discouraged many
young scientists from entering the nascent field of stem cells.
Directing induced pluripotent stem cells (iPSCs) into
midbrain dopamine neurons
With the ban in place, necessity became the mother of invention.
In just 5 short years, the scientific world found its way around
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the thorny ethical issues surrounding the use of human embryonic tissue with the revolutionary discovery of induced pluripotency. Thus, in 2006, Takahashi and Yamanaka published their
landmark study on mouse iPSCs, earning Yamanaka the Nobel
prize 6 years later. Remarkably, both the Thomson and
Yamanaka laboratories established human iPSC lines just 1 year
later (Takahashi et al., 2007; Yu et al., 2007).
Through the years of the stem cell ban, my laboratory continued to work developing a protocol to differentiate a dopamine
phenotype in hES cells (Yang et al., 2003, 2004; Iacovitti et al.,
2007) while pressing to understand how that regulation occurred
at the level of the TH gene in those cells (Romano et al., 2005,
2007; H. Jin et al., 2006). Once again, good luck played an important role in what happened next. At about this time, Jingli Cai
arrived in my laboratory as a new postdoctoral fellow having
completed her training in the premier stem cell laboratory at the
National Institutes of Health under the tutelage of Mahendra
Rao. With Jingli’s capable hands, we were well positioned to
move from predominantly hES cells to human iPSCs in the next
critical chapter of our work.
Cai’s early studies were pivotal in showing the critical role
played by the fate gene Lmx1a in the differentiation of hES cells
and iPSCs into midbrain dopamine neurons in culture (Cai et
al., 2009, 2010). Moreover, Jingli showed that stem-cell-derived
midbrain dopamine progenitors transplanted into 6-OHDAlesioned PD rats survived long-term and expressed many,
though not all, of the traits of a full authentic midbrain dopamine
phenotype. Like others in the field at that time (Arenas, 2002;
Kim et al., 2002; Hedlund et al., 2008; Lee et al., 2010; Kriks et al.,
2011), we also found a multitude of other cell types present in
midbrain dopamine-differentiated cultures and grafts (Cai et al.,
2010). Together, these issues caused us to reexamine more
closely the blueprint for midbrain dopamine differentiation in
vivo. We found that a critical balance was necessary between
reciprocally regulated Wnt and SHH pathways for the induction
of a bona fide midbrain dopamine phenotype (Cai et al., 2013).
Thus, Wnt signals, important in anterior-posterior axis development and the expression of Lmx1a in midbrain dopamine progenitors, along with SHH signals, important in ventral to dorsal
axis development and the induction of another key midbrain dopamine fate gene, Foxa2, must be present at the appropriate concentrations and times in culture, mimicking the spaciotemporal
cues driving the development of midbrain dopamine neurons in
the brain (Joksimovic et al., 2009a,b; Tang et al., 2010;
Joksimovic and Awatramani, 2014; Mesman et al., 2014).
However, it was only after initiating an important collaboration with colleagues at Jefferson, Drs. Alex Mazo and Svetlana
Petruk, that we came to appreciate how important the very earliest stages of differentiation were to the outcome of this process
in stem cells. Using a clever technique developed by the Mazo
laboratory called the chromatin assembly assay for single-cell
gene-specific analysis (Petruk et al., 2016), we showed that there
was a critical “window of opportunity” for the recruitment of lineage-specifying transcription factors, such as Lmx1a and Foxa2
to DNA. This window surprisingly occurred during the first
hours after induction of midbrain dopamine differentiation in
culture (Fig. 2) (Petruk et al., 2017).
Normally, in activating new transcriptional programs during
differentiation, transcription factors are recruited to repressed
genes in euchromatin. However, this recruitment process is
impeded by the repressive histone mark H3K27me3 on condensed chromatin. Our study revealed that, during the first hours
of midbrain dopamine differentiation in hES cells and iPSCs, the

5334 • J. Neurosci., June 23, 2021 • 41(25):5331–5337

Iacovitti · From Phenotypic Plasticity to Stem Cell Therapy

accrual of the H3K27me3 was delayed
on post-replicative DNA, indicative of a
decondensed chromatin structure. This
delay provided a window during which
Lmx1a and Foxa2 and other critical transcription factors could bind DNA to drive
forward the midbrain dopamine differentiation process (Fig. 3).
iPSCs in disease modeling
As the field amassed greater confidence in
the fidelity of the cell types being differentiated from stem cells, there was a major
shift toward disease modeling in iPSC cultures. The importance of this newfound
ability to differentiate iPSCs carrying the
patient genome into cell types relevant to
their disease cannot be overstated. It made
possible the study of pathogenic mechanisms in the dish, how gene mutations are
influenced by their environment in the
disease process, and provided a platform
to rapidly test potential new therapeutics.
Figure 2. A model for the role of post-replicative chromatin for the association of lineage-specific TFs following induction
The burgeoning literature reflected the
of ESC differentiation. In uninduced ESCs, the repressive histone mark H3K27me3-containing chromatin with a high density
stem cell revolution that was underway of nucleosomes prevents binding of unwanted transcription factors (TFs) (first row). Following induction of differentiation,
(for review, see Mattis and Svendsen, demethylation of H3K27me3 induced the lysine demethylase UTX leads to a decrease in nucleosome spacing (second row).
2011; Xie and Tang, 2016).
This “opening” of chromatin facilitates binding of the newly induced lineage-specific TFs (third row). The return of the fast
For my laboratory, this launched a mode of accumulation of H3K27me3 correlates with condensing nucleosome spacing, preventing further association of nonhighly collaborative period examining specific TFs, which may cause changes in lineage commitment (fourth row). Reprinted with permission from Petruk et al.
PD using all the tools that had been (2017).
developed in the laboratory over the
years, including iPSCs carrying PD gene
evidence of cell-to-cell spread of potentially disease-causing
mutations (LRRK2, a-synuclein triplication) as well as our
dipeptide repeat proteins (Westergard et al., 2016). More
TH-GFP reporter mouse (Kessler et al., 2003) and rat
recently, in a collaboration with Jefferson colleagues studying
(Iacovitti et al., 2014) models. Thus, with colleagues at
Charcot-Marie-Tooth disease, we developed a new gene editing
Vanderbilt, we found that TH-GFP-tagged midbrain dopaapproach to correct the disease mutation in iPSCs generated
mine neurons derived from mouse stem cells were morphofrom Charcot-Marie-Tooth patients (Cai et al., 2021).
logically and functionally indistinguishable from fetal
midbrain dopamine neurons (Gu et al., 2015). In other studGoing forward
ies with K. S. Kim (Harvard Medical School), we examined
One of our current goals is the creation of reporter iPS lines to
the role of the leucine-rich repeat kinase 2 (LRRK2) gene
help track changes in live differentiated IPSCs which would also
mutation in normal and PD brain and found that the dysenable the segregation of midbrain dopamine progenitors
function in SN dopamine neurons caused by mutant LRRK2
and/or midbrain dopamine neurons for studies in vitro and
may be directly responsible for the selective degeneration of
in vivo. Despite many years of striving to better direct the
those cells (Han et al., 2008). In a collaboration with colmidbrain dopamine differentiation process, this remains an
leagues at Hopkins, a transgenic mouse line was generated
important objective for the stem cell field in the face of
wherein 11 kb of the human TH promoter was used to drive
ongoing cell heterogeneity. In vitro, this heterogeneity creG2019S LRRK2 expression. Importantly, these mice showed
ates an environment which is not physiologically relevant,
an age- and kinase-dependent degeneration of brain cateconfounding disease modeling results. In grafts, the presence
cholamine neurons with consequent motor deficits (Xiong et
of heterogeneous cell types (including potentially excitotoxic
al., 2018). Using PD iPSCs carrying the G2019S mutation,
glutamatergic neurons) poses a major stumbling block in
Cai went on to show that the LRRK2 kinase inhibitor
moving stem cells to the clinic. Thus, we are currently workCZC54252, a potential therapeutic, could rescue midbrain
ing on the generation of Lmx1a, En1, Pitx3, and TH reporter
dopamine neurons from their deadly fate after challenge by
iPSC lines using new advances in gene editing methodologies
neurotoxins (Cai, unpublished data; Fig. 4).
(Cai et al., 2021). These reporter lines will hopefully address
Our work on iPSCs led to the establishment of the Jefferson
the vexing issue of cell heterogeneity by allowing us to FACS
Stem Cell and Regenerative Neuroscience Center in 2016. This
purify midbrain dopamine progenitors and midbrain dopagreatly expanded our reach beyond PD, allowing us to provide
mine neurons for PD modeling in culture. In addition, these
stem cells to the wider Jefferson community for the study of an
purified genetically engineered cells offer the opportunity to
array of neurodegenerative diseases. Thus, in collaborative
identify novel midbrain dopamine-specific cell surface
experiments where iPSCs from C9orf72-ALS patients were difmarkers, making it possible in the future to FACS sort nonferentiated into spinal motor neurons and used to study ALS
engineered midbrain dopamine neurons for transplantation
of replacement cells in PD patients.
pathogenic mechanisms, the Trotti/Passinelli laboratory showed
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Figure 3. Induction of expression and association with DNA of lineage-specific transcription factors during midbrain dopamine differentiation of hESCs. A, qRT-PCR gene expression analysis
of undifferentiated (0 h, control) hESCs and hESCs induced to the midbrain dopamine lineage for 6 and 12 h. B, Undifferentiated hESCs (top) and hESCs induced to the midbrain dopamine lineage for 6 or 12 h (bottom) were labeled with EdU for 15 min and then chased for 15 min. Chromatin assembly assay (CAA) is a method based on the proximity ligation assay (PLA) that allows
examination of proteins associated with nascent DNA following replication in single cells. CAA was performed for LMX1A, FOXA2, and SIP1 followed by immunostaining for biotin (green). PLA
only is shown in black and white. Quantification of the results of three independent CAA experiments is also shown (right): x axis, hours in midbrain dopamine differentiation cocktail; y axis,
number of PLA signals per nucleus. Reprinted with permission from Petruk et al. (2017).

Figure 4. LRRK2 kinase inhibitor CZC54252 rescues LRRK2 iPS-derived dopamine neurons from neurotoxin-induced cell death. A, LRRK2 G2019S iPS-derived dopamine neurons were treated
with 5 mM, 10 mM LRRK2 kinase inhibitor CZC54252 (bottom two rows), while DMSO was added to control wells (top row). On the next day, fresh medium containing neurotoxins, 200 nM rotenone (Rot, middle column) or 200 mM 1-methyl-4-phenylpyridinium (MPP1) (right column), were added together with the same doses of CZC54252. Forty-eight hours later, all wells fixed and
stained with antibodies to TH (red) and bIII tubulin (green) and counterstained with DAPI nuclear stain (blue). B, In the absence of CZC5252, rotenone or MPP1 treatment caused the death of
a large percentage of dopamine neurons (TH1). Both dosages of CZC5252 significantly increased the survival of TH1 cells both in control conditions (reason still unknown) and after treatment
with rotenone and MPP1.

Finally, the laboratory is once again captivated by another important growth factor, GDF15. Studies by Eric Kostuk, then a
graduate student in the laboratory, showed that subregional differences in midbrain astrocytes and their expression of GDF15 may
underlie the selective degeneration of SN midbrain dopamine neurons and protection of VTA dopamine neurons in models of PD.
Because the receptor for GDF15, GFRAL, is present on vulnerable
SN dopamine neurons, it may represent an important therapeutic
target in the future (Kostuk et al., 2019).

In conclusion, in looking back on my journey from there to
here, it is truly surprising to me how linear our progress now
appears. I assure you it did not seem so at the time. There were
of course many off ramps into new areas of science not discussed
here. Still, it is undeniably clear that my original passion for catecholamine differentiation and the principles that govern that
process remained an important undercurrent throughout my career. In the retelling, I am also struck by the hefty dose of good
luck that helped at each step along the way, from landing in
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laboratories with extraordinary mentors purely by happenstance
to serendipitous conversations in hallways that led to important
collaborations. Mostly, however, I recognize that whatever success the laboratory has enjoyed, is owed entirely to the exceptional students and postdocs throughout the years. These young
dedicated scientists and their passions in science promise a
bright future.

References

Arenas E (2002) Stem cells in the treatment of Parkinson’s disease. Brain Res
Bull 57:795–808.
Cai J, Donaldson A, Yang M, German MS, Enikolopov G, Iacovitti L (2009)
The role of Lmx1a in the differentiation of human embryonic stem cells
into midbrain dopamine neurons in culture and after transplantation
into a Parkinson’s disease model. Stem Cells 27:220–229.
Cai J, Yang M, Poremsky E, Kidd S, Schneider JS, Iacovitti L (2010)
Dopaminergic neurons derived from human induced pluripotent stem
cells survive and integrate into 6-OHDA-lesioned rats. Stem Cells Dev
19:1017–1023.
Cai J, Schleidt S, Pelta-Heller J, Hutchings D, Cannarsa G, Iacovitti L (2013)
BMP and TGF- b pathway mediators are critical upstream regulators of
Wnt signaling during midbrain dopamine differentiation in human pluripotent stem cells. Dev Biol 376:62–73.
Cai J, Kropf E, Hou YM, Iacovitti L (2021) A stress-free strategy to correct
point mutations in patient iPS cells. Stem Cell Res 53:102332.
Cooper O, Hargus G, Deleidi M, Blak A, Osborn T, Marlow E, Lee K, Levy
A, Perez-Torres E, Yow A, Isacson O (2010) Differentiation of human ES
and Parkinson’s disease iPS cells into ventral midbrain dopaminergic
neurons requires a high activity form of SHH, FGF8a and specific regionalization by retinoic acid. Mol Cell Neurosci 45:258–266.
Dale H (1935) Pharmacology and nerve-endings (Walter Ernest Dixon
Memorial Lecture): (Section of Therapeutics and Pharmacology). Proc R
Soc Med 28:319–332.
Du X, Iacovitti L (1995) Synergy between growth factors and transmitters
required for catecholamine differentiation in brain neurons. J Neurosci
15:5420–5427.
Du X, Stull ND, Iacovitti L (1994) Novel expression of the tyrosine hydroxylase gene requires both acidic fibroblast growth factor and an activator. J
Neurosci 14:7688–7694.
Falck B (1962) Observations on the possibilities of the cellular localization of
monoamines by a fluorescence method. ACT A Physiol A Scand A 56:1–
25.
Folkerth RD, Durso R (1996) Survival and proliferation of nonneural tissues,
with obstruction of cerebral ventricles, in a parkinsonian patient treated
with fetal allografts. Neurology 46:1219–1225.
Freed CR, Greene PE, Breeze RE, Tsai WY, DuMouchel W, Kao R, Dillon S,
Winfield H, Culver S, Trojanowski JQ, Eidelberg D, Fahn S (2001)
Transplantation of embryonic dopamine neurons for severe Parkinson’s
disease. N Engl J Med 344:710–719.
Friling S, Andersson E, Thompson LH, Jönsson ME, Hebsgaard JB, Nanou E,
Alekseenko Z, Marklund U, Kjellander S, Volakakis N, Hovatta O, El
Manira A, Björklund A, Perlmann T, Ericson J (2009) Efficient production of mesencephalic dopamine neurons by Lmx1a expression in embryonic stem cells. Proc Natl Acad Sci USA 106:7613–7618.
Gu H, Lazarenko RM, Koktysh D, Iacovitti L, Zhang Q (2015) A stem cellderived platform for studying single synaptic vesicles in dopaminergic
synapses. Stem Cells Transl Med 4:887–893.
Guo Z, Du X, Iacovitti L (1998) Regulation of tyrosine hydroxylase gene
expression during transdifferentiation of striatal neurons: changes in
transcription factors binding the AP-1 site. J Neurosci 18:8163–8174.
Hagell P, Piccini P, Björklund A, Brundin P, Rehncrona S, Widner H, Crabb
L, Pavese N, Oertel WH, Quinn N, Brooks DJ, Lindvall O (2002)
Dyskinesias following neural transplantation in Parkinson’s disease. Nat
Neurosci 5:627–628.
Han BS, Iacovitti L, Katano T, Hattori N, Seol W, Kim KS (2008) Expression
of the LRRK2 gene in the midbrain dopaminergic neurons of the substantia nigra. Neurosci Lett 442:190–194
Hedlund E, Pruszak J, Lardaro T, Ludwig W, Viñuela A, Kim KS,
Isacson O (2008) Embryonic stem cell-derived Pitx3-enhanced green
fluorescent protein midbrain dopamine neurons survive enrichment

Iacovitti · From Phenotypic Plasticity to Stem Cell Therapy
by fluorescence-activated cell sorting and function in an animal
model of Parkinson’s disease. Stem Cells 26:1526–1536.
Higgins D, Iacovitti L, Joh TH, Burton H (1981) The immunocytochemical
localization of tyrosine hydroxylase within rat sympathetic neurons that
release acetylcholine in culture. J Neurosci 1:126–131.
Hirsch E, Graybiel AM, Agid YA (1988) Melanized dopaminergic neurons
are differentially susceptible to degeneration in Parkinson’s disease.
Nature 334:345–348.
Iacovitti L (1991) Effects of a novel differentiation factor on the development
of catecholamine traits in noncatecholamine neurons from various
regions of the rat brain: studies in tissue culture. J Neurosci 11:2403–
2409.
Iacovitti L, Joh TH, Park DH, Bunge RP (1981) Dual expression of neurotransmitter synthesis in cultured autonomic neurons. J Neurosci 1:685–
690.
Iacovitti L, Johnson MI, Joh TH, Bunge RP (1982) Biochemical and morphological characterization of sympathetic neurons grown in a chemicallydefined medium. Neuroscience 7:2225–2239.
Iacovitti L, Joh TH, Albert VR, Park DH, Reis DJ, Teitelman G (1985) Partial
expression of catecholaminergic traits in cholinergic chick ciliary ganglia:
studies in vivo and in vitro. Dev Biol 110:402–412.
Iacovitti L, Teitelman G, Joh TH, Reis DJ (1987) Chick eye extract promotes
expression of a cholinergic enzyme in sympathetic ganglia in culture. Dev
Brain Res 33:59–65.
Iacovitti L, Evinger MJ, Joh TH, Reis DJ (1989) A muscle-derived factor(s)
induces expression of a catecholamine phenotype in neurons of cultured
rat cerebral cortex. J Neurosci 9:3529–3537.
Iacovitti L, Donaldson AE, Marshall CE, Suon S, Yang M (2007) A protocol
for the differentiation of human embryonic stem cells into dopaminergic
neurons using only chemically defined human additives: studies in vitro
and in vivo. Brain Res 1127:19–25.
Iacovitti L, Wei X, Cai J, Kostuk EW, Lin R, Gorodinsky A, Roman P, Kusek
G, Das SS, Dufour A, Martinez TN, Dave KD (2014) The hTH-GFP reporter rat model for the study of Parkinson’s disease. PLoS One 9:
e113151.
Jin BK, Iacovitti L (1995) Dopamine differentiation factors produce partial
motor recovery in 6- hydroxydopamine lesioned rats. Neurobiol Dis 2:1–
12.
Jin H, Romano G, Marshall C, Donaldson AE, Suon S, Iacovitti L (2006)
Tyrosine hydroxylase gene regulation in human neuronal progenitor cells
does not depend on Nurr1 as in the murine and rat systems. J Cell
Physiol 207:49–57.
Johnson MI, Iacovitti L, Higgins D, Bunge RP, Burton H (1981) Growth and
development of sympathetic neurons in tissue culture. In: Ciba Found
Symp, pp 108–122. New York: Wiley.
Joksimovic M, Awatramani R (2014) Wnt/ b -catenin signaling in midbrain
dopaminergic neuron specification and neurogenesis. J Mol Cell Biol
6:27–33.
Joksimovic M, Anderegg A, Roy A, Campochiaro L, Yun B, Kittappa R,
McKay R, Awatramani R (2009a) Spatiotemporally separable Shh
domains in the midbrain define distinct dopaminergic progenitor pools.
Proc Natl Acad Sci USA 106:19185–19190.
Joksimovic M, Yun BA, Kittappa R, Anderegg AM, Chang WW, Taketo
MM, McKay RD, Awatramani RB (2009b) Wnt antagonism of Shh facilitates midbrain floor plate neurogenesis. Nat Neurosci 12:125–131.
Kessler MA, Yang M, Gollomp KL, Jin H, Iacovitti L (2003) The human tyrosine hydroxylase gene promoter. Brain Res Mol Brain Res 112:8–23.
Kim JH, Auerbach JM, Rodríguez-Gómez JA, Velasco I, Gavin D, Lumelsky
N, Lee SH, Nguyen J, Sánchez-Pernaute R, Bankiewicz K, McKay R
(2002) Dopamine neurons derived from embryonic stem cells function in
an animal model of Parkinson’s disease. Nature 418:50–56.
Kostuk EW, Cai J, Iacovitti L (2019) Subregional differences in astrocytes
underlie selective neurodegeneration or protection in Parkinson’s disease
models in culture. Glia 67:1542–1557.
Kriks S, Shim JW, Piao J, Ganat YM, Wakeman DR, Xie Z, Carrillo-Reid L,
Auyeung G, Antonacci C, Buch A, Yang L, Beal MF, Surmeier DJ,
Kordower JH, Tabar V, Studer L (2011) Dopamine neurons derived from
human ES cells efficiently engraft in animal models of Parkinson’s disease. Nature 480:547–551.
Landis SC (1980) Developmental changes in the neurotransmitter properties
of dissociated sympathetic neurons: a cytochemical study of the effects of
medium. Dev Biol 77:349–361.

Iacovitti · From Phenotypic Plasticity to Stem Cell Therapy
Landis SC, Keefe D (1983) Evidence for neurotransmitter plasticity in vivo:
developmental changes in properties of cholinergic sympathetic neurons.
Dev Biol 98:349–372.
Le Douarin NM (1980) The ontogeny of the neural crest in avian embryo
chimaeras. Nature 286:663–669.
Lee HS, Bae EJ, Yi SH, Shim JW, Jo AY, Kang JS, Yoon EH, Rhee YH, Park
CH, Koh HC, Kim HJ, Choi HS, Han JW, Lee YS, Kim J, Li JY, Brundin
P, Lee SH (2010) Foxa2 and Nurr1 synergistically yield A9 nigral dopamine neurons exhibiting improved differentiation, function, and cell survival. Stem Cells 28:501–512.
Ma Y, Feigin A, Dhawan V, Fukuda M, Shi Q, Greene P, Breeze R, Fahn S,
Freed C, Eidelberg D (2002) Dyskinesia after fetal cell transplantation for
parkinsonism: a PET study. Ann Neurol 52:628–634.
Mattis VB, Svendsen CN (2011) Induced pluripotent stem cells: a new revolution for clinical neurology? Lancet Neurol 10:383–394.
Mesman S, Von Oerthel L, Smidt MP (2014) Mesodiencephalic dopaminergic neuronal differentiation does not involve GLI2A-mediated SHH-signaling and is under the direct influence of canonical WNT signaling.
PLoS One 9:e97926.
Morizane A, Darsalia V, Guloglu MO, Hjalt T, Carta M, Li JY, Brundin
P (2010) A simple method for large-scale generation of dopamine
neurons from human embryonic stem cells. J Neurosci Res 88:3467–
3478.
Olanow CW, Goetz CG, Kordower JH, Stoessl AJ, Sossi V, Brin MF,
Shannon KM, Nauert GM, Perl DP, Godbold J, Freeman TB (2003) A
double-blind controlled trial of bilateral fetal nigral transplantation in
Parkinson’s disease. Ann Neurol 54:403–414.
Park CH, Minn YK, Lee JY, Choi DH, Chang MY, Shim JW, Ko JY, Koh HC,
Kang MJ, Kang JS, Rhie DJ, Lee YS, Son H, Moon SY, Kim KS, Lee SH
(2005) In vitro and in vivo analyses of human embryonic stem cellderived dopamine neurons. J Neurochem 92:1265–1276.
Perrier AL, Tabar V, Barberi T, Rubio ME, Bruses J, Topf N, Harrison
NL, Studer L (2004) Derivation of midbrain dopamine neurons from
human embryonic stem cells. Proc Natl Acad Sci USA 101:12543–
12548.
Petruk S, Fenstermaker TK, Black KL, Brock HW, Mazo A (2016) Detection
of RNA-DNA association by a proximity ligation-based method. Sci Rep
19:295–306.
Petruk S, Cai J, Sussman R, Sun G, Kovermann SK, Mariani SA, Calabretta B,
McMahon SB, Brock HW, Iacovitti L, Mazo A (2017) Delayed accumulation of H3K27me3 on nascent DNA is essential for recruitment of transcription factors at early stages of stem cell differentiation. Mol Cell
66:247–257.e5.
Potter DD, Landis SC, Furshpan EJ (1981) Adrenergic-cholinergic dual function in cultured sympathetic neurons of the rat. In: Ciba Found Symp, pp
123–150. New York: Wiley.

J. Neurosci., June 23, 2021 • 41(25):5331–5337 • 5337
Romano G, Macaluso M, Lucchetti C, Iacovitti L (2007) Transcription and
epigenetic profile of the promoter, first exon and first intron of the
human tyrosine hydroxylase gene. J Cell Physiol 211:431–438.
Romano G, Suon S, Jin H, Donaldson AE, Iacovitti L (2005) Characterization
of five evolutionary conserved regions of the human tyrosine hydroxylase
(TH) promoter: implications for the engineering of a human TH minimal
promoter assembled in a self-inactivating lentiviral vector system. J Cell
Physiol 204:666–677.
Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K,
Yamanaka S (2007) Induction of pluripotent stem cells from adult human
fibroblasts by defined factors. Cell 131:861–872.
Tang M, Villaescusa JC, Luo SX, Guitarte C, Lei S, Miyamoto Y, Taketo MM,
Arenas E, Huang EJ (2010) Interactions of Wnt/beta-catenin signaling
and sonic hedgehog regulate the neurogenesis of ventral midbrain dopamine neurons. J Neurosci 30:9280–9291.
Teitelman G, Joh TH, Grayson L, Park DH, Reis DJ, Iacovitti L, (1985)
Cholinergic neurons of the chick ciliary ganglia express adrenergic traits
in vivo and in vitro. J Neurosci 5:29–39.
Thomson JA (1998) Embryonic stem cell lines derived from human blastocysts. Science 282:1145–1147.
Westergard T, Jensen BK, Wen X, Cai J, Kropf E, Iacovitti L, Pasinelli P,
Trotti D (2016) Cell-to-cell transmission of dipeptide repeat proteins
linked to C9orf72-ALS/FTD. Cell Rep 17:645–652.
Wolinsky E, Patterson PH (1983) Tyrosine hydroxylase activity decreases
with induction of cholinergic properties in cultured sympathetic neurons.
J Neurosci 3:1495–1500.
Xie N, Tang B (2016) The application of human iPSCs in neurological diseases: from bench to bedside. Stem Cells Int 2016: 1–10.
Xiong Y, Neifert S, Karuppagounder SS, Liu Q, Stankowski JN, Lee BD, Ko
HS, Lee Y, Grima JC, Mao X, Jiang H, Kang SU, Swing DA, Iacovitti L,
Tessarollo L, Dawson TM, Dawson VL (2018) Robust kinase- and age-dependent dopaminergic and norepinephrine neurodegeneration in LRRK2
G2019S transgenic mice. Proc Natl Acad Sci USA 115:1635–1640.
Yang M, Donaldson AE, Jiang Y, Iacovitti L (2003) Factors influencing the
differentiation of dopaminergic traits in transplanted neural stem cells.
Cell Mol Neurobiol 23:851–864.
Yang M, Donaldson AE, Marshall CE, Shen J, Iacovitti L (2004) Studies on
the differentiation of dopaminergic traits in human neural progenitor
cells in vitro and in vivo. Cell Transplant 13:535–547.
Yu J, Vodyanik MA, Smuga-Otto K, Antosiewicz-Bourget J, Frane JL, Tian S,
Nie J, Jonsdottir GA, Ruotti V, Stewart R, Slukvin II, Thomson JA (2007)
Induced pluripotent stem cell lines derived from human somatic cells.
Science 318:1917–1920.
Zeng X, Cai J, Chen J, Luo Y, You Z, Fotter E, Wang Y, Harvey B, Miura T,
Backman C, Chen GJ, Rao MS, Freed WJ (2004) Dopaminergic differentiation of human embryonic stem cells. Stem Cells 22:925–940.

